Tumors are comprised of both cancer cells and surrounding stromal components. As an
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Drug resistance develops in nearly all patients with colon cancer, leading to a decrease in
the therapeutic efficacies of anticancer agents. This review provides an up-to-date summary …

It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a
significant survival benefit from the sorafenib treatment, which is currently regarded as a first …

Globally, primary liver cancer is the third leading cause of cancer death, and hepatocellular
carcinoma (HCC) accounts for 75%–95%. The tumor microenvironment (TME), composed of …

In light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab plus
bevacizumab, this novel combination has become the preferred first-line standard of care for …

Immune checkpoint inhibitors (ICIs) with atezolizumab plus bevacizumab are promising
agents for unresectable hepatocellular carcinoma (HCC). We tried to guide the treatment …

Hepatocellular carcinoma (HCC) is the fifth most common cancer and is the second leading
cause of cancer death. Since the diagnosis of HCC is difficult, in many cases patients with …

The only US Food and Drug Administration (FDA)-approved first-line systemic therapy for
hepatocellular carcinoma (HCC) is sorafenib; however, resistance or intolerance to …

Primary liver cancer is one of the leading causes of cancer-related deaths worldwide. China
has more than 55% liver cancer cases globally. The development of hepatocellular …